{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:35:26Z","timestamp":1789403726777,"version":"build-2803163510"},"reference-count":75,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1080\/17425255.2024.2402931","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:36:33Z","timestamp":1725928593000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1859-7146","authenticated-orcid":false,"given":"Sophie","family":"Vieujean","sequence":"first","affiliation":[{"name":"Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, INSERM NGERE, CHRU Nancy, Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"Groupe Hospitalier priv\u00e9 Ambroise Par\u00e9 - Hartmann, Paris IBD center, Neuilly sur Seine, France"},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00966-2"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01528-8"},{"key":"e_1_3_7_11_1","unstructured":"EMA. Zeposia. European Medicines Agency; 2020 [cited 2024 Apr 1]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zeposia"},{"key":"e_1_3_7_12_1","unstructured":"VTX002 versus placebo for the treatment of moderately to severely active ulcerative colitis. [cited 2024 Jul 17]. Available from: https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2023\/03\/050181.l"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0134com"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1139221"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.165845"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091619"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx107"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1545"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01431-8"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy269"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.04.006"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.007"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S336139"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2356"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76369"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1196188"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01319-7"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13476"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2400"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.887"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01500-0"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01473-0"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.014"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.409"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030515"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211041907"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.383"},{"key":"e_1_3_7_40_1","unstructured":"Bristol Myers Squibb. Zeposia. Package insert. Celgene corporation. [cited 2024 Jul 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209899s001lbl.pdf"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab076.439"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199936060-00004"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1833106100"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000233"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.14.1295.43156"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04341.x"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad112"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000220"},{"key":"e_1_3_7_49_1","volume-title":"[Summary of product characteristics]","author":"Zeposia","year":"2023","unstructured":"Zeposia. [Summary of product characteristics]. Dublin: Bristol Myers Squibb Pharma; 2023."},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1810530"},{"key":"e_1_3_7_51_1","volume-title":"[Package insert.]","author":"Zeposia","year":"2022","unstructured":"Zeposia. [Package insert.]. Princeton (NJ): Bristol Myers Squibb; 2022."},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513248"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab012"},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000776512.86710.84"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.03.035"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08178-8"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.254268"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz203.525"},{"key":"e_1_3_7_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.494"},{"key":"e_1_3_7_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001100"},{"key":"e_1_3_7_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1785868"},{"key":"e_1_3_7_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1379"},{"key":"e_1_3_7_63_1","article-title":"Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis","volume":"30","author":"Oh DA","year":"2019","unstructured":"Oh DA, Lee CA, Tang Y, et al. Steady-state trough concentrations and their relationship to selected demographic and clinical response measures in etrasimod-treated patients with moderately-to-severely active ulcerative colitis. Turk J Gastroenterol. 2019 [cited 2024 Apr 4];30:S143\u2010S144.","journal-title":"Turk J Gastroenterol"},{"key":"e_1_3_7_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1255"},{"key":"e_1_3_7_65_1","volume-title":"Summary of Product characteristics (centralized license), applicable to all countries in the EU and Norway","author":"VELSIPITY (etrasimod)","year":"2023","unstructured":"VELSIPITY (etrasimod). Summary of Product characteristics (centralized license), applicable to all countries in the EU and Norway. Amsterdam, Netherlands: European Medicines Agency (EMA); 2023."},{"key":"e_1_3_7_66_1","volume-title":"European Public Assessment Report (EPAR)","author":"Velsipity (etrasimod)","year":"2023","unstructured":"Velsipity (etrasimod). European Public Assessment Report (EPAR). Amsterdam, Netherlands: European Medicines Agency (EMA); 2023. Available online at: Velsipity, INN-etrasimod (europa.eu). [cited 2024 Jul 11]."},{"key":"e_1_3_7_67_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"e_1_3_7_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab016"},{"key":"e_1_3_7_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00212"},{"key":"e_1_3_7_70_1","unstructured":"Ventyx biosciences announces positive results from the phase 2 trial the phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis. [cited 2024 Jul 15]. Available online https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0435379"},{"key":"e_1_3_7_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(20)33639-8"},{"key":"e_1_3_7_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac190.0878"},{"key":"e_1_3_7_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155014"},{"key":"e_1_3_7_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad212.0003"},{"key":"e_1_3_7_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otad009"},{"key":"e_1_3_7_76_1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002263"},{"key":"e_1_3_7_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.032"}],"container-title":["Expert Opinion on Drug Metabolism &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2402931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T13:20:37Z","timestamp":1727270437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2402931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1080\/17425255.2024.2402931"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2402931","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}